Chagas disease, also known as the American vector-borne disease, is a tropical parasitic disease caused by the triple-negative protozoan Trypanosoma cruzi. The disease is mainly spread by an insect called a kissing bug. The infected person's body undergoes a series of changes, among which the incubation period and symptom changes are key to understanding the disease.
Chagas disease typically occurs in two phases: an acute phase and a chronic phase.
The acute phase occurs within 1 to 2 weeks after the insect bite, and many infected people do not show obvious symptoms during this stage, which makes early diagnosis difficult. But when symptoms do occur, they are mostly mild and include fever, swollen lymph nodes and headache. In rare cases, swelling may occur at the site of infection, especially on the eyelids, which is known as the "Romaña sign".
This phase usually lasts about 4 to 8 weeks and, in untreated people, it enters a chronic phase. In most cases, there are no obvious symptoms during the chronic phase, which leads many people to not realize that they have been infected with the disease. People often wait 10 to 30 years after infection before they develop heart disease, digestive problems or other health problems, which further aggravate the disease.
About 45% of people infected in the chronic stage will develop heart disease, which may lead to heart failure.
Common complications of chronic Chagas disease include heart disease, which can cause frequent palpitations or fainting and can even lead to heart failure. In addition, approximately 10% to 21% of patients may develop digestive problems, such as an enlarged esophagus or colon, which makes it difficult for the patient to swallow or have a bowel movement. It is worth noting that chronic lesions may not cause obvious warnings, which greatly increases health risks.
Chagas disease is spread in a variety of ways, including through kissing bug bites and excrement, blood transfusions, organ transplants, and mother-to-child transmission. The prevalence of this disease and its devastating effects make prevention considerations all the more important.
There is currently no vaccine for Chagas disease, but early-stage infection can be treated with benidadazole or nifcamoc.
Existing treatments are relatively effective in early-stage infections, but their effectiveness decreases as the infection progresses. The side effects of benidazolid and nifcamox may affect patients' perseverance in treatment, so the development of new therapeutic drugs and vaccines will become an important research direction in the future.
According to statistics in 2019, approximately 6.5 million people worldwide are infected with Chagas disease, mainly in Mexico, Central America and South America. In addition to the impact on human health, the disease also imposes a significant burden on society and the economy, especially in poor areas, where many patients do not even know that they are infected with Chagas disease.
Chagas disease is a neglected tropical disease caused by the Trypanosoma cruzi parasite, which is primarily transmitted by insects that live in polluted environments. After feeding on the blood of an infected person, these insects expel the eggs of T. cruzi, which can then infect a new host. Typically, these insects are nocturnal and prefer to dwell in close proximity to humans, which makes preventive measures all the more important.
Prevention measures for Chagas disease focus on kissing bug eradication, which involves using insecticides and improving living environments to avoid insect breeding. The efforts of public health agencies have shown results in some areas, but many challenges still remain.
The medical community still needs to continue to pay attention to the prevention and control of Chagas disease, because this not only affects the health of infected people, but also concerns the health of the entire society. How will future research advance efforts to combat Chagas disease?